Today: 7 February 2026
Subscribe

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab A/S shares fell 3.3% to $30.44 in New York after the company dropped further development of acasunlimab, a late-stage cancer drug, following a portfolio review. Genmab said the move does not affect its 2025 guidance and will focus on other pipeline drugs. The company also completed its acquisition of Merus N.V., paying $97 per share in a tender offer. Merus requested Nasdaq delist its stock after the merger.
31 December 2025
···
Tesla stock today slips as TSLA braces for Q4 deliveries after Tesla posts analyst consensus

Tesla stock today slips as TSLA braces for Q4 deliveries after Tesla posts analyst consensus

Tesla shares slipped 0.2% to $453.58 late Wednesday morning as investors awaited the company’s quarterly deliveries report due Friday. Analyst consensus points to a 13% year-on-year drop in fourth-quarter deliveries, with estimates around 432,810 vehicles. South Korea’s L&F sharply reduced its battery-material supply deal with Tesla, citing lower business tied to Tesla’s battery program.
31 December 2025
···
Meta stock today: META slips after Reuters scam-ad “playbook” report as Manus AI deal stays in focus

Meta stock today: META slips after Reuters scam-ad “playbook” report as Manus AI deal stays in focus

Meta shares fell 0.4% to $663 by late morning Wednesday after a Reuters report said internal documents showed the company delayed tougher ad checks to avoid costs. The U.S. Virgin Islands sued Meta, alleging it profited from scam ads and failed to protect children. Investors are also watching Meta’s planned $2–$3 billion acquisition of AI startup Manus.
31 December 2025
·
Microsoft stock slips in late-morning trade as year-end tech selling weighs on megacaps

Microsoft stock slips in late-morning trade as year-end tech selling weighs on megacaps

Microsoft shares fell 0.5% to $484.89 in late morning trading Wednesday as investors trimmed tech holdings ahead of year-end. Holiday-thin volumes amplified moves in major tech stocks, with Broadcom down 0.7% and Nvidia up 0.7%. Wall Street’s focus remains on the Fed’s Jan. 27-28 meeting and Microsoft’s upcoming earnings, which have not yet been scheduled.
31 December 2025
··
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Micron stock slips today as China’s CXMT targets $4.2 billion DRAM IPO

Micron stock slips today as China’s CXMT targets $4.2 billion DRAM IPO

Micron Technology shares fell 1.8% to $287.35 in late-morning New York trading Wednesday after a Reuters report highlighted China’s CXMT plans to raise $4.2 billion for DRAM expansion. Micron’s CFO transferred 35,000 shares to an estate-planning trust, according to a recent filing. The company’s Taiwan unit secured a $149.5 million subsidy for memory chip R&D. Chip stocks and U.S. indexes traded slightly lower.
31 December 2025
···
Nasdaq Keeps PLTS Trading Halted With No Reason Listed as Bengaluru ‘My Room, My Rules’ Row Spreads Online

Nasdaq Keeps PLTS Trading Halted With No Reason Listed as Bengaluru ‘My Room, My Rules’ Row Spreads Online

Nasdaq kept trading in Platinum Analytics Cayman Limited (PLTS) halted Wednesday, listing the reason as “not available” as of 10:23 a.m. ET. The exchange had previously halted PLTS in October after an SEC suspension and requested more information from the company. No further details were provided in the latest notice. Separately, a Bengaluru renter’s late-night noise complaint on Reddit sparked debate over shared-living boundaries.
31 December 2025
·
Why Life360 stock is sliding today as year-end trading hits tech names

Why Life360 stock is sliding today as year-end trading hits tech names

Life360 shares fell 4.4% to $63.79 in morning Nasdaq trading, down $2.94 from Tuesday’s close, with about 108,000 shares changing hands. The drop came as tech stocks extended losses on the final trading day of 2025. Life360 recently raised its full-year revenue outlook and agreed to buy ad-tech firm Nativo for $120 million. The company’s next earnings report is set for Feb. 26.
31 December 2025
···
XPeng stock slides 6% today as Chinese EV shares retreat in thin year-end trade

XPeng stock slides 6% today as Chinese EV shares retreat in thin year-end trade

XPeng’s U.S.-listed shares fell 6% to $19.99 by late morning in New York on Wednesday, while NIO dropped 9.5% and Li Auto slid 4.8%. Traders cited thin year-end liquidity and awaited January delivery data and details on China’s updated EV subsidies. XPeng’s ADRs traded between $19.87 and $20.54, with volume near 3.9 million shares. Broader U.S. stocks also slipped ahead of the New Year’s holiday.
31 December 2025
·····
Applied Digital’s ChronoScale plan: Cloud spin-off and Ekso tie-up puts AI GPUs in focus

Applied Digital’s ChronoScale plan: Cloud spin-off and Ekso tie-up puts AI GPUs in focus

Applied Digital will spin out its cloud unit and merge it with Ekso Bionics to form ChronoScale, with Applied owning about 97% of the new company and Ekso shareholders holding about 3%, according to filings. The deal is based on a non-binding term sheet and aims to close in the first half of 2026. Applied Digital shares rose 2.4% after the announcement, while Ekso shares jumped 103%.
31 December 2025
····
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

NEW YORK, December 31, 2025, 10:33 ET — Regular session Shares of Arcutis Biotherapeutics Inc rose 3.8% to $29.16 by 10:33 a.m. ET on Wednesday, extending gains in the final U.S. trading session of 2025. The Nasdaq-listed dermatology drugmaker traded between $28.08 and $29.19, with about 181,000 shares changing hands. The move puts ARQT within striking distance of $30 and about 8% below its 52-week high of $31.75, a level closely watched by momentum investors. The stock’s 52-week low stands at $11.14, according to market data. markets.businessinsider.com That relative strength mattered on a down day for risk assets. The biotech
31 December 2025
··
1 … 643 644 645 646 647 … 1,634

Stock Market Today

Coca-Cola stock price ends near $79 — frozen products exit sets up KO earnings week

Coca-Cola stock price ends near $79 — frozen products exit sets up KO earnings week

7 February 2026
Coca-Cola will discontinue its frozen products, including the Minute Maid frozen line, in the U.S. and Canada in Q1 2026. Shares closed Friday up 0.66% at $79.03 ahead of Tuesday’s quarterly results. CEO James Quincey sold 337,824 shares on Feb. 3 for about $26 million under a pre-arranged plan. Options pricing suggests a possible 3% move after earnings.
Cisco stock jumps 3% into earnings week as tech shakeout keeps CSCO in focus

Cisco stock jumps 3% into earnings week as tech shakeout keeps CSCO in focus

7 February 2026
Cisco shares closed up 3% at $84.82 Friday after a volatile week for tech stocks. The company will report quarterly results Feb. 11, with analysts expecting EPS of $1.02 on $15.12 billion revenue. U.S. jobs and inflation data, delayed by the federal shutdown, are also due next week. About 23.9 million Cisco shares traded Friday.
Go toTop